Flocoumafen

Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects^[1][2][3]. In Vitro:Flocoumafen best compound is prostaglandin F synthase and serum albumin (binding affinity ≥ 14.0 kcal/mol), followed by glucocorticoid receptor 2, matrix metalloproteinase-9, nuclear receptor ROR-alpha, and activin receptor type-1, with a binding affinity of ≥ 13.5 kcal/mol^[1]. In Vivo:Flocoumafen (0.02-0.1 mg/kg, once a week for 14 weeks) accumulates residues in the liver of rats and cannot be completely metabolized, showing anticoagulant toxicity at high doses^[3].